Kv1-Complex Autoantibody Detection for Neurological Disorder Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing autoimmune neurological disorders, such as limbic encephalitis and Morvan's syndrome, are inadequate as they fail to accurately detect autoantibodies targeting voltage-gated potassium channel (VGKC) complex proteins, leading to incomplete understanding and treatment of these conditions.
Innovation Solution
A method and kit for diagnosing autoimmune neurological disorders by detecting autoantibodies to epitopes of Kv1-complex proteins, including CASPR2, Lgi1, and TAG1, which are associated with these conditions, using immunological assays and bodily fluid samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to detect autoantibodies, then the diagnostic process is simple, but the detection accuracy and completeness are insufficient
Solution Approach 1:
The diagnostic method is segmented into multiple specific detection steps targeting different Kv1-complex proteins (Kv1.1, Kv1.2, Kv1.6, CASPR2, Lgi1, TAG1) individually. This segmentation allows each protein to be detected with optimized specificity while maintaining an overall systematic approach that improves comprehensive detection accuracy without excessive complexity
Solution Approach 2:
The patent uses iodinated alpha-dendrotoxin (I125-αDTX) as an intermediary mediator that specifically binds to Kv1 potassium channels. This intermediary enables indirect detection of autoantibodies through their effect on the toxin-channel interaction, providing enhanced detection sensitivity and accuracy while maintaining methodological simplicity
2Loss of information
If autoantibodies to multiple Kv1-complex proteins are detected, then the diagnostic completeness improves, but the time required for diagnosis increases
Solution Approach 1:
The patent combines multiple detection targets (Kv1.1, Kv1.2, Kv1.6, CASPR2, Lgi1, TAG1) into a unified diagnostic framework using a common detection platform. This merging approach allows simultaneous assessment of multiple autoantibody targets within a single diagnostic workflow, achieving comprehensive diagnostic information without proportionally increasing time investment
Solution Approach 2:
The patent employs preliminary identification of clinically suspected cases based on symptom profiles (limbic encephalitis, Morvan's syndrome, neuromyotonia) before applying the full multi-target detection protocol. This preliminary action filters patients strategically, ensuring comprehensive multi-protein detection is applied where most needed, thereby reducing overall diagnostic time while maintaining completeness
3Adaptability or versatility
If specific autoantibody targets are identified, then the treatment guidance improves, but the complexity of the detection system increases
Solution Approach 1:
The detection system is designed with universal applicability across multiple neurological conditions (limbic encephalitis, Morvan's syndrome, neuromyotonia, epilepsy) by targeting the common Kv1-complex protein family. This universal platform provides treatment guidance versatility for different diseases without requiring separate specialized detection systems for each condition, thereby avoiding excessive complexity while maintaining adaptability
Solution Approach 2:
The patent applies different detection sensitivities and specificities to different protein targets based on their clinical relevance and antibody prevalence. High-prevalence targets like Kv1.1 and Kv1.2 use optimized detection parameters, while rarer targets like TAG1 use more sensitive but selective methods. This local quality optimization provides nuanced treatment guidance for each protein target while balancing overall system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise identification of specific neurological disorders and associated risks, improving diagnosis and potentially guiding targeted treatments by correlating autoantibody titers with clinical features.
Implementation Method 1
detecting, in a bodily fluid sample from the mammal, autoantibodies to an epitope of at least one Kv1-complex protein
Data Source
AI summary
The invention relates to a method of diagnosing an autoimmune neurological disorder in a mammal comprising the step of detecting, in a bodily fluid sample from the mammal, autoantibodies to an epitope of at least one Kv1-complex protein; and related methods, assay kits, isolated or purified autoantibody or antibody fragments, or uses thereof.